EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer

Cengiz Karacin iD, Veli Sunar, Zuhat Urakci iD, Ali Yilmaz, Murat Ayhan, Mustafa Ersoy, Deniz Can Guven iD, Ismail Erturk, Yasin Durmus, Pinar Karacin, Nurettin Boran, Yaprak Engin Ustun und 8 weitere

Future Oncology · 2024

DOI: 10.2217/fon-2023-0763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Cengiz Karacin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Peritoneal Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded.

Results

The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8).

Conclusion

Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsPeritoneal NeoplasmsCystadenocarcinoma, SerousHumansFemaleAdultMiddle AgedAgedBevacizumabRetrospective Studies

Stichwörter der Autor:innen

bevacizumablow gradeovarian cancerperitoneumseroustuba

Substanzen

Bevacizumab

Autor:innen und Institutionen

  • Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey.
  • Depatment of Medical Oncology, Losante Children & Adult Hospital, Ankara, Turkey.
  • Departmen of Medical Oncology, Dicle University, Diyarbakir, Turkey.
  • Department of Medical Oncology, Atatürk University Training Hospital, Erzurum, Turkey.
  • Department of Medical Oncology, Kartal Training & Research Hospital, Istanbul, Turkey.
  • Department of Medical Oncology, Osmangazi University, Eskisehir, Turkey.

ORCID-Profile: Cengiz Karacin, Zuhat Urakci, Deniz Can Guven, Mutlu Dogan, Yakup Ergun

Zitieren

APA

Karacin, C., Sunar, V., Urakci, Z., Yilmaz, A., Ayhan, M., Ersoy, M., Guven, D. C., Erturk, I., Durmus, Y., Karacin, P., Boran, N., Ustun, Y. E., Meydan, M., Dogan, M., Oksuzoğlu, B., Ates, O., Karaca, M., Uncu, D., Ergun, Y., & Arik, Z. (2024). Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer. Future Oncology. https://doi.org/10.2217/fon-2023-0763

Vancouver

Karacin C, Sunar V, Urakci Z, Yilmaz A, Ayhan M, Ersoy M, et al. Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer. Future Oncology. 2024. doi:10.2217/fon-2023-0763

BibTeX
@article{Karacin2024,
  author = {Karacin, Cengiz and Sunar, Veli and Urakci, Zuhat and Yilmaz, Ali and Ayhan, Murat and Ersoy, Mustafa and Guven, Deniz Can and Erturk, Ismail and Durmus, Yasin and Karacin, Pinar and Boran, Nurettin and Ustun, Yaprak Engin and Meydan, Mutlu and Dogan, Mutlu and Oksuzoğlu, Berna and Ates, Ozturk and Karaca, Mustafa and Uncu, Dogan and Ergun, Yakup and Arik, Zafer},
  title = {Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-0763}
}
Kostenlos starten →